Allegiance Equity Announces Private Placement

Monday, 31 January 2011 09:28 AM

TORONTO, ONTARIO -- Allegiance Equity Corporation (TSX-VENTURE: ANQ)
 
The Board of Directors of the Corporation has authorized a private placement of up to 500,000 common shares at $0.20 per share to replace previously announced Private Placement of December 17 th ,2010.
 
Purpose of Financing.
Allegiance is in discussions with several potential licensees for the distribution and licensing of it’s two exciting products, Relieva TM and CinGx TM. Funding will be used for the following purposes:

1. Facilitate the commercialization of Relieva and CinGx TM.
 
The Board of Directors previously announced Private Placement of 500,000 common shares at $0.25 on December 17 th 2010 which did not proceed.
 
CinGx TM for Prevention and Treatment of Diabetes,Alzheimer`s and Dementia.

Allegiance created and developed CinGx TM,  for the treatment and prevention of Alzheimer`s Dementia and Diabetes.

CinGx TM contains two natural concentrated and purified ingredients that act synergistically to control glucose metabolism, and improve brain function,  to minimize the risk of developing dementia.(Rx of Diabetes & Dementia).

There are numerous applications for CinGx TM in a multitude of food products, beverages, diet foods, nutritional products, meal replacement bars and shakes, vitamin products and diabetic products. Health Canada issued EXEMPTION NUMBER -140568 2010-08-18 and has approved a strong set of compelling health claims and benefits for label labelling and advertising purposes, including:

• Reduces blood sugar
• Reduces cholesterol
• Reduces triglycerides
• Acts as an antioxidant
• Improves cognitive function
• Improves memory
• Improves mental well being
• Improves vitality of life

CinGx TM is patented and its claims are approved by the International PCT Examiner under Publication No. WO 2010/048705.

Allegiance is in negotiation with a national ingredient company for the distribution of CinGx TM to its customers

RELIEVA TM

Prime Pharmaceutical Corporation (Prime) a subsidiary of Allegiance invented a patented extraction process which increases the concentration of the beneficial alkaloids from Mahonia Aquifolium by up to 75 times to create its proprietary extract Psorberine TM

Reliéva™ is made with Psorberine™ an anti-inflammatory, antibacterial product for the treatment of psoriasis and atopic dermatitis. Relieva™ provides immediate relief for itching, irritation and inflammation associated with almost all problem skin conditions with zero toxicity and irritation.

Prime is pursuing several licensing opportunities for RelievaTM with two multinationals as well as a Spanish Pharmaceutical Company. These companies are in their initial stages of due diligence. Prime is also continuing to work with DSE Health Solutions LLC  Edison New Jersey. They have decided not to proceed with the enhanced formulation as regulatory compliance in the U.S.for the enhanced version would be costly.

ABOUT ALLEGIANCE

Allegiance provides financial and business assistance to corporations in various industries including the pharmaceutical, medical and biotechnology industries, and assists them in raising the capital The Company and its partners develop innovative new treatments for widespread diseases and medical conditions where existing treatments fail to meet the needs of patients.

Interest of Management  Notice of Intention to Distribute.

Palm American Investment Inc. holds 1, 771,998 common shares of Allegiance Equity. Palm American Investment Inc is controlled by David Solomon, Marilyn Bloovol and members of their family. It is contemplated, corporations controlled by Marilyn Bloovol and David Solomon, directors and officers of Allegiance may participate in the private placement, directly or indirectly through corporations controlled by them. Palm American Investment Inc. filed a Notice of Intention to sell up to 1,000,000 common shares on  January 17th, 2011 by way of private sale or on the market from time to time.

Allegiance Equity Corporation (ANQ) is the largest shareholder of Prime and holds 6,045,000 shares out of 16,259,580, which is approximately 37.5% of Prime. There are presently 5,978,558 common shares of Allegiance issued and outstanding.

Additional information relevant to the Company's activities, including the Company's press releases can found on SEDAR at www.sedar.com.


The TSX Venture Exchange has not reviewed and does not accept responsibility FOR THE ADEQUACY OR ACCURACY FOR THIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY MANAGEMENT.


Contact:
Allegiance Equity Corporation
David Solomon
President
(416) 630 1221
Email: [email protected]
www.allegianceequity.com